[0001] The present invention concerns a composition of substances, preferably obtained from
natural sources, effective in the prevention and/or therapeutic treatment of osteoarticular
diseases, particularly arthritis.
[0002] The term "arthritis" refers to all disorders affecting the joints. In all cases the
patients are affected by pain and stiffness of the joints. There are about 100 different
types of arthritis of which the most common are rheumatoid arthritis and osteoarthritis.
[0003] Rheumatoid arthritis is an autoimmune disorder that mainly involves the joints, which
become swollen and painful. The disease may also affect other parts of the body, leading
for example to a reduction in the number of red blood cells, the appearance of inflammation
around the heart and lungs, fever and a general sense of fatigue.
[0004] It is believed that this disease is due to a combination of genetic and environmental
factors. The main mechanism involves the activation of the immune system against the
joints, which leads to inflammation and thickening of the articular capsule, also
involving the bone and cartilage. The initial site of the disease is the synovial
membrane, where there is an infiltration of cells of the immune system. More specifically,
rheumatoid arthritis is generally characterized by the succession of three phases:
an initial phase due to non-specific inflammation, an amplification phase involving
the activation of T cells, and finally a final phase of chronic inflammation due to
the release of pro-inflammatory cytokines, such as interleukin-2, γ-interferon, tumor
necrosis factor (TNF) and interleukin-6.
[0005] The main risk factors for rheumatoid arthritis are gene mutations that involve disorders
in the regulation of the immune response. One of the gene mutations responsible for
the etiology of rheumatoid arthritis is localized in genes involved in the expression
of the class 2 major histocompatibility complex (MHC) such as HLA DR4. Other documented
environmental factors include, for example, smoking.
[0006] Osteoarthritis (osteoarthrosis or arthrosis) is a degenerative disease of the joints
that affects millions of people around the world mainly in the hips, hands and knees.
It is well known that the synovia, bone and cartilage are the tissues most involved
in the pathological mechanisms of osteoarthritis.
[0007] The cause of the disease is likely to be related to changes in the homeostasis of
the joint cartilage and bone that lead to the increase of destructive processes. In
osteoarthritis there is a change in the structure of the bone and a degeneration of
the joint cartilage. The subchondral bone becomes rigid, less capable of absorbing
impact loads, which leads to greater stress on the cartilage. In fact, the main characteristics
of the disease include a progressive loss of cartilage tissue, hypertrophic bone modifications
and formation of osteophytes that grow at the edges of the bones involved.
[0008] With reference to cartilage, it is known that chondrocytes are the cells responsible
for balancing the processes of synthesis and destruction of the matrix, capable of
regulating cytokines and growth factors. In degenerative osteoarticular processes,
this balance is usually compromised. In patients with osteoarthritis, chondrocytes
produce high levels of inflammatory cytokines such as interleukin 1-β and tumor necrosis
factor (TNF), which in turn reduce collagen synthesis and increase concentrations
of catabolic mediators such as metalloproteases. At the same time, other pro-inflammatory
substances such as interleukin-8 (IL-8) and interleukin-6 (IL-6), prostaglandin E2
and nitric oxide are released. The increase of oxidizing agents such as nitric oxide
determines the apoptosis of chondrocytes and thus the degeneration of the matrix.
[0009] In addition to the inflammatory process, another event typically found in osteoarthritis
is a progressive reduction in the level of proteoglycans. Without the protective effect
of proteoglycans, the cartilage becomes much more susceptible to degeneration and
degradation. Aggrecan is considered the main proteoglycan responsible for providing
hydration and elasticity to cartilage tissues, and, in patients with osteoarthritis,
a reduction in its concentration is observed.
[0010] Moreover, several studies have shown that chondrocytes are also responsible for the
production of reactive oxygen species (ROS), such as superoxide anions (O
2-) and hydroxyl radicals (OH
-). This effect is mainly due to the activation of macrophages and neutrophils, which
take part in the inflammatory response.
[0011] The most documented risk factors for osteoarthritis are age, sex, obesity, genetics
and trauma which may determine the onset of the physiopathology of osteoarthritis.
Age is the main risk factor, as it is known that with increasing age the tensile properties
of the articular cartilage decrease, leading to mechanical problems. Women normally
show greater pain and disability than men. People with a high body mass index are
more at risk.
[0012] The most common symptoms of osteoarthritis include chronic pain, due to an increased
concentration at the affected sites of excitatory amino acids such as glutamate, which
contributes to hyperalgesia and pain. Another characteristic symptom is articular
rigidity due to a decrease in the levels of surfactant phospholipids responsible for
reducing friction ensuring optimal lubrication.
[0013] Due to changes in, for example, the articular cartilage in the knee, additional effects
appear in patients, including edema of the underlying soft tissues, blood circulation
disorders, bone enlargement and swelling.
[0014] The phannacological treatments traditionally used in osteoarticular diseases are
primarily represented by analgesic drugs, which help to reduce the sensation of pain
but, obviously, do not represent anything but symptomatic treatments. Anti-inflammatory
drugs of various kinds (nonsteroidal and steroidal) are also used to counteract the
inflammatory processes that characterize the disease. However, these drugs require
numerous daily administrations to reach adequate therapeutic doses and often have
serious side effects, such as peptic ulcers or gastric perforations. The use of selective
COX-2 NSAIDs (such as Celecoxib) reduces this type of event, but at the same time
may cause serious damage to the cardiovascular system. Paracetamol has fewer side
effects but is only indicated in mild to moderate forms of osteoarthritis.
EP2149378 A1 discloses a composition comprising capsaicin, boswellic acids and escin for use in
treating osteoarthritis.
[0015] There is therefore a need to provide treatments, alternative to those already existing,
that are effective in the prevention and/or therapeutic treatment of osteoarticular
diseases, but that do not have the side effects and/or disadvantages of treatments
in the state of the art.
[0016] These and other needs are met by the present invention, which provides a composition
characterized in that it comprises a synergistic combination of active ingredients,
obtained from natural sources, the aforesaid combination having proved particularly
effective against osteoarticular diseases.
[0017] The composition of the invention is as defined in the accompanying claim 1. Further
features and advantages of the invention are defined in the dependent claims. The
claims form an integral part of the present description.
[0018] Hereinafter a detailed description of some of the preferred embodiments of the invention
is provided.
[0019] The synergistic composition of the present invention is useful for the treatment
and prevention of osteoarticular diseases.
[0020] In the composition of the present invention, the synergistic action takes place between
aescin, at least one extract of a plant belonging to the genus
Boswellia, preferably at least one extract of
Boswellia serrata, and an extract of
Scutellaria baicalensis.
[0021] Boswellia serrata belongs to the family
Burseraceae and to the genus
Boswellia and is a tree of moderate size that grows in the mountainous areas of India, North
Africa and Middle East. The most interesting part of the plant from a pharmacological
point of view is the gum-resin or frankincense that is obtained by an incision of
the trunk. This oily resin contains about 30-60% resin, 5-10% essential oil, and the
remaining part polysaccharides, such as arabinose, galactose, xylose. Due to the essential
oil, the resin has a particular aroma that justifies its use in aromatherapy. The
resin also contains monoterpenes (α-thujene), diterpenes (macrocyclic diterpenes such
as incensole, incensole oxide, iso incensole oxide, serratol), triterpenes (such as
α and β amyrin), pentacyclic triterpene acids (boswellic acids) and tetracyclic triterpene
acids.
[0022] Boswellic acids are the main secondary metabolites of frankincense with anti-inflammatory
and anti-tumor activity. Clinical studies have shown the effectiveness of
Boswellia-based preparations in the treatment of inflammatory diseases, such as osteoarthritis,
rheumatoid arthritis, chronic inflammatory intestinal diseases, as well as in the
treatment of asthma and cancer.
[0023] Several mechanisms have been proposed for the action of boswellic acids on inflammation.
For example, 3-O-Acetyl-11-ketoboswellic acid is able to interfere with several pathways,
including the NF-κB pathway and the Mitogen-Activated Protein kinase (MAP kinase)
pathway. In addition, the ability of boswellic acids to interact with 5-lipoxygenase
(5-LOX) and cyclooxygenase isoform 1 (COX-1) has been demonstrated.
[0024] A potentially interesting action mechanism is the inhibition of microsomal prostaglandin
E2 synthase type 1 (mPGES-1). PGES, prostaglandin E synthase, is an enzyme involved
in the last step of the biosynthetic pathway of PGE2, which consists in the conversion
of PGH2, the synthesis of which is catalyzed by cyclooxygenase, into PGE2. It has
been shown that the mPGES-1 isoform may be induced by pro-inflammatory stimuli, such
as interleukin-1β (IL-1β) and lipopolysaccharide (LPS). In addition, mPGES-1 receives
prostaglandin H2 preferentially from the COX-2 enzyme, since the two enzymes are co-expressed
and colocated and their expression may be induced by pro-inflammatory stimuli. Inflammation,
pain and fever may be induced by PGE2 derived from over-expression of this enzyme.
Inhibition of mPGES-1 may be effective in the treatment of inflammatory diseases,
prostaglandin E2-induced hyperalgesia and fever. All boswellic acids have good inhibitory
activity against mPGES-1, however β-boswellic acid has been shown to be one of the
most active, with an IC
50 of 10 µM in intact A549 cell assays. Assays
in vivo on acute inflammation models (carrageenan edema and pleurisy) have shown good activity
at doses of 1 mg/kg, comparable to a dose of 5 mg/kg of indomethacin.
[0025] Boswellic acids are also able to limit
in vivo the degradation of glycosaminoglycans induced by treatment with NSAIDs (ketoprofen),
which accelerates joint damage in situations of arthritis.
[0026] In a clinical study carried out on 30 patients with osteoarthritis of the knee, the
administration of 1 g of
Boswellia per day was shown to reduce pain and swelling and also increase mobility compared
to the placebo. In combination with curcumin, Indian ginseng and zinc,
Boswellia extract has been shown to reduce pain severity and disability in patients with osteoarthritis.
Finally, in a comparative study with a placebo,
Boswellia intake reduced the intake of NSAIDs during treatment in patients with rheumatoid
arthritis by about twice as much as the placebo.
[0027] Aesculus Hippocastanum L. is a large tree known as the horse-chestnut or conker tree, belonging to the
Hippocastanaceae family. The drug consists of dried seeds, which contain no less than 3% of triterpene
glycosides. The main chemical constituents characteristic of the drug are collectively
known as aescin, a name that represents a mixture of acrylated triterpene glycosides
(saponins), the aglycones of which are mainly protoaescigenin and barringtogenol C.
The difference between these aglycones is due to the presence of hydroxyl in the C-24
position of the protoaescigenin molecule. All the saponins of the horse-chestnut have
a trisaccharide group bound in the C-3 position consisting of glucuronic acid which
may be combined with glucose, galactose or xylose. The two main saponins, both derived
from protoaescigenin, are esterified in position 21β with angelic acid and in position
22α with acetic acid. To date, 30 different saponins contained in aescin have been
identified, which may be grouped in three fractions: β-aescin, which contains only
22-O-acetyl compounds; cryptoaescin, which contains only 28-O-acetyl compounds; α-aescin,
which is a mixture of β-aescin and cryptoaescin. Other drug constituents include flavonoids
(di- and triglycosides of quercetin and kaempferol, which make up 0.3% of the drug),
sterols, an essential oil and a significant amount of starch.
[0028] Aescin and the saponin fractions of the drug exert an anti-inflammatory activity,
demonstrated in several animal experiments: inhibition of the edema induced by albumin
or carrageenan in the rat's paw or inhibition of exudative edema induced by dextran
in the rat's skin; the mechanism on which this activity depends seems to be the inhibition
of the prostaglandin synthetase enzyme, as shown by an
in vitro experiment with a saponin fraction. According to the scientific literature, aescin
is able to act at different levels in the pathway of glucocorticoids by stimulating
the release thereof or increasing the expression of receptors with consequent stimulation
of the anti-inflammatory effect. In a study on rats with induced arthritis, the combination
of prednisone (2 mg/kg/day) and aescin (5 or 10 mg/kg/day) proved effective with synergistic
action in reducing the paw edema by reducing the expression of cytokines such as TNF-α,
interleukin 1-β and interleukin 6.
[0029] In a different experiment, a saponin fraction (7.5 mg/kg) administered to the rat
orally was shown to exert significant analgesic activity. The clinical effects of
the saponin fractions of the drug have been evaluated in several trials. In placebo-controlled
crossover studies conducted on women suffering mainly from varicose veins and chronic
venous insufficiency, oral administration twice daily for 20 days of a 300 mg dose
of a saponin fraction (corresponding to 50 mg aescin) resulted in a significant reduction
of various leg symptoms: edema, inflammation, pain, and also itching, pressure sensitivity,
pigmentation, fatigue, heaviness and cramp. In a randomized, double-blind, placebo-controlled
study, the anti-edema effect of a saponin fraction administered for 6 weeks to 39
patients at a daily dose corresponding to 150 mg of aescin was tested. It may therefore
be deduced that the ideal daily dose of triterpene glycosides calculated as aescin
is between 50 and 150 mg/day.
[0030] Scutellaria baicalensis is a plant belonging to the family
Lamiaceae cultivated in China, Japan, Korea. In these countries, the monograph of the plant
is included in the official pharmacopoeia.
[0031] The root extracts are particularly rich in flavonoids which are responsible for the
characteristic yellow color. Many biological properties have been described for this
plant: anti-inflammatory, antiviral, anti-tumor, antioxidant and immunostimulant.
[0032] In traditional medicine the plant has been used to treat allergic conditions, inflammatory
gastrointestinal viral infections, respiratory infections, bile infections, etc.
[0033] The flavonoids present in the plant are probably the most active components from
a pharmacological point of view. Several studies in the literature demonstrate the
anti-inflammatory efficacy of baicalin, which may reduce levels of NF-κB and COX-2
in rats while increasing levels of superoxide dismutase. This compound is also able
to act at the level of INOS causing an inhibition of this enzyme involved in the synthesis
of nitric oxide and vasodilatation typical of inflammatory processes.
[0034] In the treatment of osteoarthritis,
Scutellaria baicalensis extract, together with an
Acacia catechu extract, has been shown to inhibit the activity of COX 1 and 2 and 5-LOX in cellular
and animal models.
[0035] The therapeutic efficacy of the association of
Scutellaria baicalensis and
A. catechu has also been assessed on men with osteoarthritis of the knee. In this study, patients
received a combination of the two extracts (500 mg) or naproxen (440 mg) for a treatment
period of one week. The study has demonstrated that the combination of the two extracts
is able to reduce pain perception and stiffness in a manner comparable to naproxen
and improve joint flexibility. The safety profile and tolerability of the combination
of
Scutellaria extract with
Acacia catechu extract have been assessed in 59 patients with osteoarthritis of the knee, administering
a total of 500 mg/day for 12 weeks. The preparation has proven to be safe and with
minor side effects compared to the placebo, wherein the respiratory side effects were
actually greater (scutellaria 2).
[0036] The anti-inflammatory activity exerted by the flavonoids present in the
Scutellaria baicalensis extracts is of particular interest in the field of application of the present invention;
in fact, the administration of this extract could ensure a reduction in the symptoms
of osteoarthritis with a good profile of safety and tolerability.
[0037] As indicated previously, the synergistic composition of the present invention is
effective in the treatment and/or prevention of osteoarticular diseases. To summarize,
the effectiveness of the composition derives from the following activities of the
components:
- Extracts of plants belonging to the genus Boswellia and in particular of Boswellia serrata are inhibitors of 5-LOX and mPGES-1 with anti-inflammatory and analgesic activity;
- Aescin, preferably obtained from an extract of Aesculus hippocastanum, has an anti-edema and anti-inflammatory action;
- Due to its flavonoids, Scutellaria baicalensis extract is able to inhibit NF-κB and COX-2 by also increasing the superoxide dismutase
levels.
[0038] As discussed previously, in the present invention, the synergistic action takes place
between aescin, at least one extract of a plant belonging to the genus
Boswellia, preferably at least one extract of
Boswellia serrata, and an extract of
Scutellaria baicalensis.
[0039] In a preferred embodiment, aescin is administered in a daily dose of between 1 mg
and 5000 mg, for example by administering a dosage form wherein aescin is present
in a quantity of between 0.5% and 70% w/w, more preferably in a quantity of between
2 and 50% by weight of the total weight of the composition; at least one extract of
a plant belonging to the genus
Boswellia, preferably at least one extract of
Boswellia serrata, is administered in a daily dose of between 10 mg and 5000 mg, for example by administration
of a dosage form wherein the aforesaid at least one extract is present in a quantity
of between 1 and 90% w/w, more preferably in a quantity of between 5 and 80% by weight
of the total weight of the composition;
Scutellaria baicalensis extract is administered in a daily dose of between 1 mg and 5000 mg, for example
by administration of a dosage form wherein the aforesaid extract is present in a quantity
of between 0.5 and 70% w/w, more preferably in a quantity of between 2 and 50% by
weight of the total weight of the composition.
[0040] The dosage form may be a pharmaceutical composition or a food supplement or a medical
device or a food for special medical purposes including the aforementioned active
ingredients in a mixture. The preferred route of administration is oral or topical.
[0041] The following examples are provided purely for illustrative purposes and are not
intended to limit the scope of the invention as defined in the accompanying claims.
EXAMPLES
[0042] The following examples concern any form of pharmaceutical dosage that is acceptable,
preferably oral or topical, suitable in the scope of the present invention.
[0043] Some examples of formulations are given, with the quantities of the relative active
substances present in each dosage unit.
EXAMPLE 1
[0044]
| Active ingredient |
Daily dose |
| Boswellia serrata e.s. |
1 g |
| Aescin from Aesculus Hippocastanum |
50 mg |
| Scutellaria baicalensis e.s. |
250 mg |
EXAMPLE 2
[0045]
| Active ingredient |
Daily dose |
| Boswellia serrata e.s. |
500 mg |
| Aescin from Aesculus Hippocastanum |
100 mg |
| Scutellaria baicalensis e.s. |
50 mg |
EXAMPLE 3
[0046]
| Active ingredient |
Daily dose |
| Boswellia serrata e.s. |
1200 mg |
| Aescin from Aesculus Hippocastanum |
40 mg |
| Scutellaria baicalensis e.s. |
50 mg |
EXAMPLE 4
[0047]
| Active ingredient |
Daily dose |
| Boswellia serrata e.s. |
350 mg |
| Aescin from Aesculus Hippocastanum |
20 mg |
| Scutellaria baicalensis e.s. |
150 mg |
EXPERIMENTAL PART
[0048] The synergistic action of the composition with respect to the individual active ingredients
is evaluated using experimental methods
in vitro and/or
in vivo.
[0049] Various cell studies are able to provide important information about the anti-inflammatory
capacity of bioactive compounds able to inhibit cytokine expression. IC50 studies
are able to provide information for cellular inhibition. To evaluate in more detail
the response (inhibition/activation) of cytokines (TNF-α, IL-1, IL-4, IL-6, IL-8,
IL-10,IL-17, INF-Y, COMP) during inflammatory processes induced by LPS, the "Whole
Blood Assay (WBA)" or the "peripheral blood mononuclear cell" (PBMC) test or other
similar tests are used.
[0050] As an
in vivo test, a simple model of general inflammation is the model of carrageenan-induced
edema in mice or rats. In this test, the injection of carrageenan into the animal's
paw results in an acute inflammatory reaction of the paw with the appearance of classic
signs of inflammation; this reaction reaches its maximum within 3 hours after inoculation.
This test may be used to assess the ability of the active ingredients of the present
invention to reduce the edema of the paw induced by the injection of carrageenan.
[0051] More complex methods that are used for the evaluation of osteoarticular diseases
are for example the model of arthritis induced by collagen and arthritis induced by
Freund's adjuvant, which allow evaluating the effects of potential agents in the treatment
of arthritis for a prolonged period of time.
1. A composition comprising aescin, at least one extract from a plant belonging to the
genus Boswellia and one extract from Scutellaria baicalensis.
2. The composition according to claim 1, wherein aescin is present in the composition
in an amount ranging from 0.5% to 70% by weight on the total weight of the composition,
preferably in an amount ranging from 2 to 50% by weight on the total weight of the
composition.
3. The composition according to any of claims 1 or 2, wherein the at least one extract
from a plant belonging to the genus Boswellia is present in the composition in an amount ranging from 1 to 90% by weight on the
total weight of the composition, preferably in an amount ranging from 5 to 80% by
weight on the total weight of the composition.
4. The composition according to any one of claims 1 to 3, wherein the Scutellaria baicalensis extract is present in the composition in an amount ranging from 0.5 to 70% by weight
on the total weight of the composition, preferably in an amount ranging from 2 to
50% by weight on the total weight of the composition.
5. The composition according to any one of claims 1 to 4, wherein the plant belonging
to the genus Boswellia is Boswellia serrata,
6. The composition according to any one of claims 1 to 5, wherein aescin is present in
the composition as an extract from Aesculus hippocastanum.
7. The composition according to any one of claims 1 to 6, which is a pharmaceutical composition,
a dietary supplement, a medical device, a food for special medical purposes, a cosmetic
for oral or topical administration.
8. The composition according to any one of claims 1 to 7, for use in the prevention and/or
therapeutic treatment of osteoarticular diseases.
9. The composition for use according to claim 8, wherein the osteoarticular diseases
are rheumatoid arthritis and/or osteoarthritis.
1. Zusammensetzung, aufweisend Aescin, mindestens ein Extrakt aus einer Pflanze, die
zur Gattung der Boswelia gehört, und ein Extrakt aus Scutellaria baicalensis.
2. Zusammensetzung nach Anspruch 1, wobei Aescin in der Zusammensetzung in einer Menge
von 0,5 bis 70 Gew.-% bezogen auf das Gesamtgewicht der Zusammensetzung, bevorzugt
in einer Menge von 2 bis 50 Gew.-% bezogen auf das Gesamtgewicht der Zusammensetzung
enthalten ist.
3. Zusammensetzung nach einem der Ansprüche 1 oder 2, wobei das mindestens eine Extrakt
aus einer Pflanze, die zur Gattung der Boswelia gehört, in der Zusammensetzung in einer Menge von 1 bis 90 Gew.-% bezogen auf das
Gesamtgewicht der Zusammensetzung, bevorzugt in einer Menge von 5 bis 80 Gew.-% bezogen
auf das Gesamtgewicht der Zusammensetzung enthalten ist.
4. Zusammensetzung nach einem der Ansprüche 1 bis 3, wobei das Scutellaria baicalensis-Extrakt in der Zusammensetzung in einer Menge von 0.5 bis 70 Gew.-% bezogen
auf das Gesamtgewicht der Zusammensetzung, bevorzugt in einer Menge von 2 bis 50 Gew.-%
bezogen auf das Gesamtgewicht der Zusammensetzung enthalten ist.
5. Zusammensetzung nach einem der Ansprüche 1 bis 4, wobei die zur Gattung der Boswelia gehörige Pflanze eine Boswelia serrata ist.
6. Zusammensetzung nach einem der Ansprüche 1 bis 5, wobei Aescin in der Zusammensetzung
als Extrakt aus Aesculus hippocastanum enthalten ist.
7. Zusammensetzung nach einem der Ansprüche 1 bis 6, welche eine pharmazeutische Zusammensetzung,
ein Nahrungsergänzungsmittel, ein Medizinprodukt, ein Nahrungsmittel für spezielle
medizinische Zwecke, ein Kosmetikum zur oralen oder topischen Verabreichung ist.
8. Zusammensetzung nach einem der Ansprüche 1 bis 7 zur Verwendung in der Prävention
und/oder der therapeutischen Behandlung osteoartikulärer Erkrankungen.
9. Zusammensetzung zur Verwendung nach Anspruch 8, wobei die osteoartikulären Erkrankungen
rheumatoide Arthritis und/oder Osteoarthritis sind.
1. Composition comprenant de l'aescine, au moins un extrait d'une plante appartenant
au genre Boswellia et un extrait de Scutellaria baicalensis.
2. Composition selon la revendication 1, dans laquelle l'aescine est présente dans la
composition dans une quantité comprise dans la plage de 0,5 % à 70 % en poids, sur
la base du poids total de la composition, de préférence dans une quantité comprise
dans la plage de 2 à 50 % en poids, sur la base du poids total de la composition.
3. Composition selon l'une des revendications 1 ou 2, dans laquelle l'extrait d'une plante
appartenant au genre Boswellia, au moins au nombre de un, est présent dans la composition dans une quantité comprise
dans la plage de 1 à 90 % en poids, sur la base du poids total de la composition,
de préférence dans une quantité comprise dans la plage de 5 à 80 % en poids, sur la
base du poids total de la composition.
4. Composition selon l'une quelconque des revendications 1 à 3, dans laquelle l'extrait
de Scutellaria baicalensis est présent dans la composition dans une quantité comprise dans la plage de 0,5 à
70 % en poids, sur la base du poids total de la composition, de préférence dans une
quantité comprise dans la plage de 2 à 50 % en poids, sur la base du poids total de
la composition.
5. Composition selon l'une quelconque des revendications 1 à 4, dans laquelle la plante
appartenant au genre Boswellia est Boswellia serrata,
6. Composition selon l'une quelconque des revendications 1 à 5, dans laquelle l'aescine
est présente dans la composition en tant qu'extrait d'Aesculus hippocastanum.
7. Composition selon l'une quelconque des revendications 1 à 6, qui est une composition
pharmaceutique, un complément alimentaire, un dispositif médical, un aliment destiné
à des fins médicales spéciales, un produit cosmétique destiné à une administration
par voie orale ou topique.
8. Composition selon l'une quelconque des revendications 1 à 7, à utiliser dans la prévention
et/ou le traitement thérapeutique de maladies ostéoarticulaires.
9. Composition à utiliser selon la revendication 8, dans laquelle les maladies ostéoarticulaires
sont la polyarthrite rhumatoïde et/ou l'ostéoarthrite.